A Phase I, Randomized, Single-blind, Placebo-controlled, Sequential-group, Single-center Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of AZD7594 Given Once Daily as Inhaled Formulation in Healthy Japanese Men
Phase of Trial: Phase I
Latest Information Update: 21 Feb 2018
At a glance
- Drugs AZD 7594 (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors AstraZeneca
- 20 Jun 2016 Status changed from suspended to completed.
- 10 May 2016 Status changed from recruiting to suspended as study is on hold from 2016-04-06 until mid June, depending on the result of an amendment to study D3741C0004.)
- 19 Jan 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.